| Bioactivity | SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment[1]. |
| Target | IC50: 29nM/20 nM (hSGLT1/ hSGLT2). |
| Name | SGL5213 |
| CAS | 1240305-17-2 |
| Formula | C37H55N3O8 |
| Molar Mass | 669.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kuroda S, et al. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. Bioorg Med Chem. 2019 Jan 15;27(2):394-409. |